VXRT:OTCMKTS
Vaxart Inc
0,43 US$
arrow_downward
-0,02%(-0,000075) 1D
9 tet, 4:00:00 m.d., GMT-4 · USD
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për VXRT...
Hap
0,44 US$
I lartë
0,45 US$
I ulët
0,43 US$
Kapitalizimi i tregut
106,59 mln
Vëllimi mesatar
265,13 mijë
Vëllimi
198,22 mijë
Raporti çmim/fitim
2,66
Maksimumi 52-javor
0,84 US$
Minimumi 52-javor
0,30 US$
Fitimet për aksion
0,16 US$
Beta
1,05
Aksionet në qarkullim
242,84 mln
Numri i punonjësve
65
Hap
0,44 US$
I lartë
0,45 US$
I ulët
0,43 US$
Kapitalizimi i tregut
106,59 mln
Vëllimi mesatar
265,13 mijë
Vëllimi
198,22 mijë
Raporti çmim/fitim
2,66
Maksimumi 52-javor
0,84 US$
Minimumi 52-javor
0,30 US$
Fitimet për aksion
0,16 US$
Beta
1,05
Aksionet në qarkullim
242,84 mln
Numri i punonjësve
65
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
Brave New Coin
·
27 minuta më parë
Evernorth XRP Treasury Merger Brings 473 Million XRP to Nasdaq as XRPN Debuts October 12
Yahoo Finance
·
18 minuta më parë
How to Beat a Choppy Market With 4 Steady Stocks
AOL.com
·
35 minuta më parë
The S&P 500 Just Hit a Record High -- Here's How Much Higher It Can Climb, According to the Wall Street Consensus
24/7 Wall St.
·
3 orë më parë
KLA Turned $1,000 Into $31,595 in a Decade, Crushing the S&P 500 by 8.7x
Profili
Vaxart, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines administered using temperature-stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection. Its development programs for oral vaccine delivery include prophylactic, enteric-coated tablet vaccines for inhibiting norovirus, seasonal influenza, respiratory syncytial virus, and human papillomavirus. It was founded in 2004 by Sean Tucker. Originally incorporated as West Coast Biologicals, Inc. in California in 2004, the company later changed its name to Vaxart, Inc. in July 2007, after reincorporating in Delaware. A significant development in the company's history was the reverse merger with Aviragen Therapeutics, Inc. on February 13, 2018, which led to Vaxart becoming a wholly owned subsidiary of Aviragen. Post-merger, the company continued as Vaxart, Inc.
Vaxart's development portfolio includes a range of oral vaccines targeting infectious diseases such as norovirus, COVID-19, and seasonal influenza, as well as therapeutic vaccines like those targeting HPV. Wikipedia
Rreth Vaxart Inc
Drejtori ekzekutiv-
Punonjësit65
Themeluar mëmar 2004
SeliaSouth San Francisco, Kalifornia, Shtetet e Bashkuara të Amerikës
Sektori-
Uebsajtivaxart.com